Skip to main content

Table 3 Characteristics of the study population (n=1,096)

From: Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study

Factor/strata n %
Female gender 372 33.9%
Non Italian nationality 284 25.9%
Risk group Heterosexual 421 38.4%
  Homo/bisexual 213 19.4%
  IDU 199 18.2%
  Other/unknown 263 24.0%
CDC stage A 495 45.2%
  B 229 20.9%
  C 372 33.9%
HIV subtype B 284 25.9%
  28_BF 84 7.7%
  17_BF 48 4.4%
  F1 27 2.5%
  Other 48 4.4%
  Unknown 557 50.8%
First-line anti-HIV therapy (encoding i) 2NRTI+1NNRTI 227 20.7%
  2NRTI+1PI 214 19.5%
  2NRTI+1PI/r 426 38.9%
  Other combination 229 20.9%
First-line anti-HIV therapy (encoding iv) Truvada® + Sustiva® 47 4.3%
  Atripla® 14 1.2%
  Reyataz® ± ritonavir + backbone 22 2.0%
  Kaletra® + backbone 389 35.5%
  Any other NRTI+NNRTI 165 15.0%
  Any other NRTI+PI 221 20.2%
  Any other NRTI+PI/r 18 1.6%
  Other combinations 220 20.1%
Non-anti-HIV therapies (concomitant) anti-TB 140 12.8%
  anti-PCP 425 38.8%
  anti-HCV 14 1.3%
  other antibiotics 194 17.7%
  other drugs 238 21.7%
HBsAg negative 978 89.2%
  positive 56 5.1%
  unknown 62 5.7%
HCVAb negative 771 70.3%
  positive 247 22.5%
  unknown 78 7.1%
Discontinuation/switch for adverse events 302 27.5%
Discontinuation/switch for other causes 618 56.4%
Non-discontinued first-line anti-HIV therapies 176 16.1%
Years 1988-1993 1994-1998 1999-2004 2005-2010
Discontinuation/switch for adverse events 17 92 108 85
Patients starting a first-line ART 88 229 349 430
PYFU 282.06 350.26 724.36 504.58
Numerical markers Median IQR
Calendar year 2003 1998-2006
Days on first-line anti-HIV therapy 379 131-855
Age (years) 36 31-43
Years from the first HIV positive test 0.5 0.1-3.4
HIV-RNA Log10 copies/mL 4.8 4.7-5.2
CD4+ T cells/mm3 194 122-233